Skip to main content

Table 1 Baseline characteristics of the 53 patients

From: Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study

 

Mean ± SD

Control group (n = 23)

Diabetic group (n = 30)

Sex (male/female)

5/18

17/13

Age (year)

43.5 ± 16.5

68.5 ± 7.4

Height (cm)

165.2 ± 11.3

160.7 ± 8.4

Weight (kg)

60.9 ± 15.0

62.6 ± 13.4

BMI (kg/m2)

22.0 ± 3.3

24.1 ± 3.9

SBP (mmHg)

116.2 ± 11.5

134.8 ± 17.0

DBP (mmHg)

69.1 ± 9.1

73.5 ± 9.0

Duration of diabetes (year)

 

14.7 ± 11.5

HbA1c (%)

 

6.7 ± 0.6

Creatinine (mg/dl)

 

0.87 ± 0.26

eGFR (mL/min/1.73 m2)

 

63.5 ± 14.8

Neuropathy, n (%)

 

8 (26.7)

Retinopathy, n (%)

 

3 (10.0)

Nephropathy, n (%)

 

6 (20.0)

Anti-diabetes treatment

  

 Diet only, n (%)

 

1 (3.0)

 SU, n (%)

 

0 (0)

 Glinide, n (%)

 

2 (6.7)

 DPP-4 inhibitor, n (%)

 

21 (70.0)

 Biguanide, n (%)

 

15 (50.0)

 Thiazolidine, n (%)

 

5 (16.7)

 SGLT-2 inhibitor, n (%)

 

7 (23.3)

 α-glucose inhibitor, n (%)

 

7 (23.3)

 GLP-1 receptor, n (%)

 

3 (10.0)

 Insulin, n (%)

 

6 (20.0)

  1. Sex, by χ2 test. Age, by Welch test. BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, eGFR estimated glomerular filtration rate, SU sulfonylureas, DPP-4 inhibitor dipeptidyl peptidase-4 inhibitor, SGLT-2 inhibitor sodium-glucose transporter-2 inhibitor, GLP-1 receptor Glucagon-like peptide-1 receptor